Submission Deadline: October 31, 2025

Chief-Collection Editor:

Dr. Zhe Wang  
The First Affiliated Hospital of Zhengzhou University

 

Co-Collection Editors:

Dao Xin  
The First Affiliated Hospital of Zhengzhou University

 

Feng Wang  
The First Affiliated Hospital of Zhengzhou University

 

Topical Collection Information:

Dear Colleagues,

In recent years, cancer immunotherapy has transformed the treatment landscape for a variety of malignancies. However, significant challenges remain in optimizing treatment strategies, predicting patient response, overcoming resistance mechanisms, and integrating immunotherapy into multimodal regimens.

This special issue aims to provide a comprehensive update on recent clinical advances in cancer immunotherapy, including but not limited to:

• Biomarker discovery and predictive tools for immunotherapy response
• Clinical trials involving checkpoint inhibitors, bispecific antibodies, and cancer vaccines
• Combination therapies, such as immunotherapy plus chemotherapy, radiotherapy, or targeted therapy
• Mechanisms of resistance and novel strategies to overcome them
• Real-world evidence and translational insights from bench to bedside
• Immunotherapy in special populations, including elderly patients and those with rare cancers

We welcome high-quality original research articles, clinical studies, and in-depth reviews that explore the current landscape and future directions of cancer immunotherapy from a clinical perspective.

Guest Editor(s)
Dr. Zhe Wang
Dao Xin
Feng Wang

Keywords:

• Immunotherapy
• Cancer, Biomarkers
• Immune Checkpoint Inhibitors
• Resistance Mechanisms
• Combination Therapy
• Clinical Trials, Translational Oncology
• Tumor Microenvironment, Real-World Evidence